Glyburide, an antistroke agent, was incorporated into the PLGA nanoparticle cores, followed by coating with the NSC membrane engineered with CXCR4; this strategy was used for the stroke-targeting delivery and stroke treatment due to the interaction of SDF-1-CXCR4 axis [139]. The gene discussed is CXCR4; the disease is stroke disorder.